Andere Sprachen MINAPHARM Pharmaceuticals

Aktien

MIPH

EGS380G1C011

MIPH

Schlusskurs Egyptian Exchange Andere Börsenplätze 00:00:00 04.07.2024			% 5 Tage	% 1. Jan.
192 ^EGP	0.00%		0.00%	-11.81%

30.05.	MINAPHARM Pharmaceuticals meldet Ergebnis für das erste Quartal zum 31. März 2024	CI
07.04.	MINAPHARM Pharmaceuticals meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

MINAPHARM Pharmaceuticals Reports Earnings Results for the First Quarter Ended March 31, 2024	30.05.
MINAPHARM Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2023	07.04.
SaudiVax, Minapharm, and MiGenTra Sign a Memorandum of Understanding towards a Strategic Partnership in Saudi Arabia and the Gulf Cooperation Countries	05.10.23
SaudiVax, Minapharm, and MiGenTra Sign a Memorandum of Understanding towards a Strategic Partnership in Saudi Arabia and the Gulf Cooperation Countries This landmark MOU marks a significant step towards ensuring national health security and achieving biomanufacturing autonomy in Saudi Arabia	04.10.23
MINAPHARM Pharmaceuticals Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	29.08.23
MINAPHARM Pharmaceuticals Reports Earnings Results for the First Quarter Ended March 31, 2023	29.05.23
MINAPHARM Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2022	30.03.23
Participants Dosed of Adessia® in Germany in a Phase 1 Trial, a First for an Adalimumab Biosimilar Candidate Developed in Africa	06.03.23
Participants Dosed of Adessia® in Germany in a Phase 1 Trial, a First for an Adalimumab Biosimilar Candidate Developed in Africa This follows a prior announcement made by Minapharm Pharmaceuticals on February 13, 2023 reporting that said Phase 1 trial received unconditional approval from the Paul-Ehrlich Institut (PEI)	06.03.23
Bioventure, Minapharm Pharmaceuticals and Migentra Sign an Exclusive Agreement for the Commercialization of Multiple Biosimilar Candidates of Alvotech in the Middle East and Africa	30.11.22
Bioventure, Minapharm Pharmaceuticals and MiGenTra Sign an Exclusive Agreement for the Commercialization of Multiple Biosimilar Candidates of Alvotech in the Middle East and Africa	29.11.22
Bioventure, Minapharm Pharmaceuticals and MiGenTra Sign an Exclusive Agreement for the Commercialization of Multiple Biosimilar Candidates of Alvotech in the Middle East and Africa According to the agreement, Minapharm Pharmaceuticals and MiGenTra GmbH will share responsibilities in the Territory to file, launch and commercialize Alvotech's portfolio of licensed biosimilars once approved	29.11.22
MINAPHARM Pharmaceuticals Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	29.11.22
MINAPHARM Pharmaceuticals Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	11.08.22
MINAPHARM Pharmaceuticals Reports Earnings Results for the First Quarter Ended March 31, 2022	02.06.22
MINAPHARM Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2021	31.03.22
MINAPHARM Pharmaceuticals Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	30.11.21
MINAPHARM Pharmaceuticals Reports Consolidated Earnings Results for the Six Months Ended June 30, 2021	31.08.21
MINAPHARM Pharmaceuticals Reports Standalone Earnings Results for the Six Months Ended June 30, 2021	12.08.21
MINAPHARM Pharmaceuticals Announces Consolidated Earnings Results for the Quarter Ended March 31, 2021	16.06.21

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen MINAPHARM Pharmaceuticals

Aktien

MIPH

EGS380G1C011

MIPH

Andere Sprachen

Filter